$599

Roche Q2 ’26 Earnings; New Retatrutide Ph3 Data; Trinity Biotech Partners with Latch Medical; Dexcom Joins FDA TEMPO Pilot Program

A series of cardiometabolic-related news items has been observed from Roche, Lilly, Trinity Biotech, and Dexcom. Below, FENIX provides highlights and insights for the respective news items, including insight into Lilly’s retatrutide regulatory strategy.

This content is for Read Less members only.
Already a member? Log in here